No published human studies have shown that CJC-1295 causes cancer. However, this is not the same as saying the question has been thoroughly investigated and ruled out. The honest picture is more complicated. There is a plausible biological concern based on the general physiology of growth hormone and IGF-1. Direct data on cancer outcomes specific to CJC-1295 simply do not exist, however, within the peer-reviewed literature searched for this series. This distinction between „lack of evidence of harm” and „proven safety” is profoundly important for a question this serious and is addressed with appropriate diligence here.
Does CJC-1295 cause cancer?
There is no clinical trial, case-controlled study, or long-term cohort study identified in the peer-reviewed literature that directly measures cancer incidence in individuals using CJC-1295. This means that this article cannot point to direct evidence in humans, either confirming or refuting cancer risk from this particular compound.
What actually exists is a legitimate, general concern rooted in well-established endocrinology. IGF-1 – a hormone that CJC-1295 is specifically designed to raise – is recognised within mainstream medical science as having growth-stimulating, or „mitogenic”, effects on cells. This means it can stimulate cell division and proliferation as part of its normal biological role in the body. This is the fundamental reason why IGF-1 and the broader growth hormone-IGF-1 axis have long been an area of general research interest in oncology. Aberrant or excessive cell growth signalling is relevant to how some cancers develop and progress.
Reflecting this, a 2026 review, specifically covering performance-enhancing peptides acting on the growth hormone–IGF-1 axis, including CJC-1295, described „biologically plausible, yet unproven, mitogenic concerns” as part of the safety profile for this class of compounds [1]. This is a precise and appropriately cautious way of framing where the science currently stands. The concern is real and rooted in known biology. However, it remains unproven and theoretical specifically for CJC-1295, rather than demonstrated by any direct study measuring actual cancer outcomes in individuals who have used it.
Taking this into account, it would be inaccurate to state that CJC-1295 „causes cancer” – which is not supported by any direct evidence – nor that it is „safe with regard to cancer” – which is also not something current research can confirm. The accurate position is this: the theoretical concern exists and remains unresolved, due to a lack of dedicated long-term human studies.
Risk of heart attack with CJC-1295 – what the studies show
No published clinical trials identified in the reviewed literature for this series have specifically measured the incidence of myocardial infarction, cardiovascular events, or long-term cardiac outcomes in individuals using CJC-1295. Therefore, no direct evidence is available, either confirming or refuting cardiovascular risk specific to this compound.
Short-term human studies that exist for CJC-1295 were designed to measure hormonal responses - growth hormone and IGF-1 levels - over a period of a few weeks. No serious adverse reactions were reported in them during this timeframe. However, cardiovascular-specific safety analysis was not a primary objective of these studies and was not reported in detail [2].
It is worth making this clear. The absence of a reported cardiac event during a brief, small hormonal response study is reassuring as far as it goes. However, it is not equivalent to a dedicated cardiovascular safety study. Nor does it address what might happen with longer-term use or higher doses outside of monitored clinical conditions.
Broader reviews of growth hormone axis-modulating peptides as a class have noted endocrine and metabolic disturbances – including effects on blood glucose regulation – as part of the recognised adverse effect profile of this drug class. Metabolic disturbances of this nature are generally relevant to cardiovascular health in general medicine. Though this represents a general observation at the class level, rather than a specific, confirmed finding of cardiac risk for CJC-1295 itself [1].
Given the complete absence of dedicated cardiovascular outcome studies for this specific compound, no evidence-based claim regarding the risk of myocardial infarction can be made in either direction. This remains an open question requiring further investigation, rather than a settled one.
Long-term side effects of CJC-1295
Currently, there are no published studies analysing the effects of using CJC-1295 for months or years. This means long-term side effects remain truly unknown, rather than just unlikely or well-characterised.
Human studies that generated the main safety data cited throughout this series were short-term. The main CJC-1295 study lasted for periods of 28 and 49 days. It was also conducted on a small number of healthy adult volunteers under direct clinical supervision – a very different scenario from prolonged, unsupervised use over a longer period [2].
Many recent scientific reviews covering this broader category of growth hormone stimulators have explicitly acknowledged this gap. They state outright that rigorous, long-term safety data in humans remains scarce for these unapproved compounds, and that the real potential for harm exists precisely because this long-term picture has not been established [1], [3].
Limitations of current evidence
Regarding cancer risk, cardiovascular risk, and long-term side effects, the pattern is the same. Available short-term clinical trials for CJC-1295 have not identified serious adverse events. However, none of them were designed or large enough to detect rare, delayed, or long-latent outcomes such as cancer or cardiovascular disease. These typically require years of follow-up in much larger populations to assess them properly.
The theoretical concern around the growth-stimulating effects of IGF-1 is rooted in real, established biology. However, it remains a theoretical concern for this specific compound, rather than a demonstrated risk. The same applies to cardiovascular safety. This is a significant and solid limitation of the current evidence base – not a minor quibble.
Disclaimer
This content is for educational and informational purposes only. It should not be interpreted as medical advice, diagnosis, or a guarantee of safety. CJC-1295 remains a research compound and is not approved by the FDA or European Medicines Agency for any medical use. No published human studies have measured cancer incidence, cardiovascular events, or long-term health outcomes specifically for this compound, meaning these risks remain unanswered questions rather than established facts in either direction. Any individual with a personal or family history of cancer, cardiovascular disease, or other serious medical conditions should discuss any consideration of research peptides with a qualified healthcare professional prior to use.
[1] Dominikowski, A., Rękoś, Z., Olejarz, M., Szczepanek-Parulska, E., Domin, R., & Ruchała, M. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: Bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 17, Article 1822475. https://doi.org/10.3389/fendo.2026.1822475
[2] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. Advance online publication. https://doi.org/10.1007/s40279-026-02437-0